This week on BioTech Nation, what is AI-Powered Biology? Dr. Shana Kelley, President of Bioengineering and Head of Biohub, Chicago for the Chan-Zuckerberg Initiative, discusses how AI can be used to accelerate research, interpret data, and transform how new discoveries are made.

This week on Biotech Nation, Heather Turner of LB Pharmaceuticals joins to discuss a drug that’s new to the US, but not-so-new to Europe, where it’s already been in use for a couple of years. Intended for managing neuropsychiatric conditions like Schizophrenia, the drug is taken by several million people, but the approval process in the US has had to start back at square one. We look at why that is, and how LB is working on it.

When you think of FUJIFILM, you might be picturing rolls of camera film...but it turns out that's not all they've been working on. FUJIFILM Biotechnologies Chairman Toshi Iida joins to share more about how they're innovating in the world of biotech.

What if chemotherapy could be delivered in a focused way, directly to a tumor, and only where it's needed? Intensity Therapeutics Founder, President, & CEO Lew Bender shares how they're working to change how chemotherapy is delivered to solid tumors, personalized for each patient, with the hopes of reducing the toll it takes on the body.

This week on BioTech Nation, Jeff Liter of Luminary Therapeutics shares how his team is taking a new approach to advanced cell therapy, in the hopes of making it more accessible and affordable. Rather than formulating a custom treatment using a patient's own cells, they use healthy donor cells that are ready to go. This approach could help more people get treated for cancer and autoimmune diseases like lupus, with just a single dose.

On this episode of Biotech Nation...the story of how the United States' pharmaceutical industry came to be, and the people behind it all. Barry Werth joins Moira to discuss his new book, “The Age of Cures: How American Scientists Saved Your Life", about a handful of individuals who revolutionized research and helped build the drug development ecosystem we have today.

On this episode of BioTech Nation...Dr. James Mackay joins to talk about the progress Crystalys Therapeutics is making in the treatment of gout - a disease that affects more than 13 million people in the United States alone. Dr. Mackay debunks some common misconceptions surrounding the disease, and explains what Crystalys is doing to change the way doctors treat gout going forward.

You've probably heard of Peptides...but what exactly are they? And how do we know which ones are effective, and safe? Dr. Karsten Eastman, Co-Founder and CEO of Sethera Therapeutics, joins to answer all our questions about Peptides, and to tell us about Sethera's latest efforts to enhance peptides to make new medicines. Their plan: to develop a drug using enhanced peptides for Triple-Negative Breast Cancer... and they've already received funding.